Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/cts.12827 http://scihub22266oqcxt.onion/10.1111/cts.12827 32475019!7300626!32475019     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Transl+Sci 2020 ; 13 (5): 880-885 Nephropedia Template TP {{tp|p=32475019|t=2020. Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19 |pdf=|usr=}}{{32475019}} gab.com Text Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19 JO: Clin Transl Sci http://www.kidney.de/pget.php?&tw=1&pmid=32475019 #FOAvip Since December 2019, a novel coronavirus (severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2)) infection has been rapidly spreading worldwide and causing the respiratory illness, coronavirus disease 2019 (COVID-19). The antiretroviral drug favipiravir (FPV) has been experimentally used for COVID-19 treatment since March 2020 in Japan. However, the pharmacokinetics of FPV in critically ill patients is unknown. We measured the serum concentration of FPV using high-performance liquid chromatography in patients with severe COVID-19 who were admitted to the intensive care unit and placed on mechanical ventilation. The patients were administered 1,600 mg of FPV twice daily on day 1, followed by 600 mg twice daily from day 2 to day 5 (or more if needed). Suspensions of FPV tablets were administered through a nasogastric tube. Seven patients were enrolled in this study. Forty-nine blood samples were obtained from the eligible patients to evaluate FPV concentration. The FPV trough (after 8-12 hours) concentrations of most samples were lower than the lower limit of quantification (1 microg/mL) and half-maximal effective concentration (9.7 microg/mL) against SARS-CoV-2 previously tested in vitro. FPV trough concentration in critically ill patients was much lower than that of healthy subjects in a previous clinical trial, which is a cause for great concern. Further study is required to determine the optimal strategy for treatment of patients with severe COVID-19. Twit Text FOAVip Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19 ????Clin Transl Sci http://www.kidney.de/pget.php?&tw=1&pmid=32475019 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32475019 #FOAvip English Wikipedia <ref>{{Cite pmid|32475019}}</ref> Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19 #MMPMID32475019 Irie K; Nakagawa A; Fujita H; Tamura R; Eto M; Ikesue H; Muroi N; Tomii K; Hashida T Clin Transl Sci 2020[Sep]; 13 (5): 880-885 PMID32475019show ga Since December 2019, a novel coronavirus (severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2)) infection has been rapidly spreading worldwide and causing the respiratory illness, coronavirus disease 2019 (COVID-19). The antiretroviral drug favipiravir (FPV) has been experimentally used for COVID-19 treatment since March 2020 in Japan. However, the pharmacokinetics of FPV in critically ill patients is unknown. We measured the serum concentration of FPV using high-performance liquid chromatography in patients with severe COVID-19 who were admitted to the intensive care unit and placed on mechanical ventilation. The patients were administered 1,600 mg of FPV twice daily on day 1, followed by 600 mg twice daily from day 2 to day 5 (or more if needed). Suspensions of FPV tablets were administered through a nasogastric tube. Seven patients were enrolled in this study. Forty-nine blood samples were obtained from the eligible patients to evaluate FPV concentration. The FPV trough (after 8-12 hours) concentrations of most samples were lower than the lower limit of quantification (1 microg/mL) and half-maximal effective concentration (9.7 microg/mL) against SARS-CoV-2 previously tested in vitro. FPV trough concentration in critically ill patients was much lower than that of healthy subjects in a previous clinical trial, which is a cause for great concern. Further study is required to determine the optimal strategy for treatment of patients with severe COVID-19. |Adult[MESH] |Aged[MESH] |Amides/administration & dosage/*pharmacokinetics[MESH] |Betacoronavirus/*isolation & purification[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/blood/diagnosis/*drug therapy/virology[MESH] |Critical Illness/*therapy[MESH] |Dose-Response Relationship, Drug[MESH] |Drug Administration Schedule[MESH] |Female[MESH] |Humans[MESH] |Intubation, Gastrointestinal[MESH] |Male[MESH] |Pandemics[MESH] |Pneumonia, Viral/blood/diagnosis/*drug therapy/virology[MESH] |Pyrazines/administration & dosage/*pharmacokinetics[MESH] |Respiration, Artificial[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH] |Suspensions[MESH] |Tablets[MESH]Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-(epmc).pdf DeepDyve Pubget Overpricing